MedTrace Logo

Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma

NCT02437812 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-02-28

No results posted yet for this study

Summary

Initially, the prospect of metformin as a neoplastic treatment was considered for malignancies of the prostate, colon and pancreas. However, only select clinical studies involving the use of metformin in the treatment of ovarian cancer have documented improved survival rates. Since no first line regimen has demonstrated compelling superiority in the management of advanced stage ovarian carcinoma, the combination of paclitaxel, carboplatin, and metformin is of particular interest given the triplet's prospect for achieving increased synergy without compromising patient tolerability.

Conditions

  • Epithelial Ovarian Carcinoma

Interventions

DRUG

Metformin

Metformin with standard chemotherapy

DRUG

Paclitaxel

Standard chemotherapy

DRUG

Carboplatin

Standard chemotherapy

Sponsors & Collaborators

  • University of North Carolina, Chapel Hill

    collaborator OTHER

  • Gynecologic Oncology Associates

    lead OTHER

Principal Investigators

  • Lisa N Abaid, M.D., M.P.H. · Gynecologic Oncology Associates

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2017-10-31
Completion
2021-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02437812 on ClinicalTrials.gov